Artificial intelligence breakthroughs are transforming cancer care with novel diagnostic and therapeutic applications. Researchers have developed AI models for detecting prostate cancer overlooked by pathologists and Bufalin identified via AI as an estrogen receptor degrader in hormone-responsive cancers. Tempus AI's $81 million acquisition of Paige will expand digital pathology datasets to fuel large foundation models for oncology. Deep learning methods also enable improved MRI-based prediction of prostate cancer spread, advancing personalized treatment planning.